ArticleTherapeutic advances in medical oncology2026
The role of thoracic radiotherapy in the setting of immunotherapy in polymetastatic esophageal squamous cell carcinoma: a multi-center cohort study.
Article in Therapeutic advances in medical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05142709 (Real-world Experience of Anti-PD-1 Immunotherapy Plus Chemotherapy as First-line Treatment for Patients With Advanced Oesophageal Squamous Cell Carcinoma in China), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Real-world Experience of Anti-PD-1 Immunotherapy Plus Chemotherapy as First-line Treatment for Patients With Advanced Oesophageal Squamous Cell Carcinoma in China(REACTION Trial).
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The efficacy of immunochemotherapy (ICT) remains poor in patients with polymetastases from esophageal squamous cell carcinoma (ESCC). While radiation therapy (RT) has shown promise in oligometastatic settings, its role when combined with ICT for polymetastatic ESCC (with >5 metastatic lesions) remains unclear. Objective: This study evaluated the efficacy and value of RT in patients with polymetastatic ESCC who received ICT as first-line treatment. Design: This multi-center cohort study was conducted at 20 hospitals in China. Methods: In total, 331 patients who received at least one cycle of first-line ICT between January 2019 and December 2021 were enrolled. Among them, 88 received ICT plus RT (RT group), and 243 received ICT alone (non-RT group). Propensity score matching (PSM) was performed to control for potential confounders (75 patients/group). Outcomes included overall survival (OS), progression-free survival, objective response rate (ORR), symptom control, and safety. This study was registered at the Clinicaltrials.gov registry (identification number NCT05142709). Results: Both before and after PSM, no significant OS benefit was observed with RT group (median OS: 15.2 vs 12.2 months, hazard ratio (HR) 0.80 (0.60-1.07), Conclusion: For polymetastatic ESCC, RT combined with ICT enhanced symptom control without severe toxicity, though it did not improve survival. This supports its personalized use for quality of life in symptomatic patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.